Peter Welford
Stock Analyst at Jefferies
(1.68)
# 2,117
Out of 4,479 analysts
9
Total ratings
100%
Success rate
12.73%
Average return
Main Sectors:
Top Industries:
4 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GSK GSK | Maintains: Buy | $53 → $53 | $38.00 | +39.49% | 2 | Jul 2, 2024 | |
| AZN AstraZeneca | Downgrades: Hold | n/a | $77.06 | - | 4 | Jan 3, 2024 | |
| GLPG Galapagos NV | Upgrades: Hold | $49 → $47 | $25.31 | +86.49% | 2 | Jan 23, 2023 | |
| GMAB Genmab | Downgrades: Hold | n/a | $24.82 | - | 1 | Sep 16, 2021 |
GSK
Jul 2, 2024
Maintains: Buy
Price Target: $53 → $53
Current: $38.00
Upside: +39.49%
AstraZeneca
Jan 3, 2024
Downgrades: Hold
Price Target: n/a
Current: $77.06
Upside: -
Galapagos NV
Jan 23, 2023
Upgrades: Hold
Price Target: $49 → $47
Current: $25.31
Upside: +86.49%
Genmab
Sep 16, 2021
Downgrades: Hold
Price Target: n/a
Current: $24.82
Upside: -